Diagnosis and treatment of Alzheimer disease and related disorders - Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society

被引:243
作者
Small, GW
Rabins, PV
Barry, PP
Buckholtz, NS
DeKosky, ST
Ferris, SH
Finkel, SI
Gwyther, LP
Khachaturian, ZS
Lebowitz, BD
McRae, TD
Morris, JC
Oakley, F
Schneider, LS
Streim, JE
Sunderland, T
Teri, LA
Tune, LE
机构
[1] JOHNS HOPKINS UNIV, BALTIMORE, MD USA
[2] BOSTON UNIV, BOSTON, MA 02215 USA
[3] NIA, BETHESDA, MD 20892 USA
[4] UNIV PITTSBURGH, PITTSBURGH, PA USA
[5] NYU, NEW YORK, NY USA
[6] NORTHWESTERN UNIV, CHICAGO, IL 60611 USA
[7] DUKE UNIV, DURHAM, NC USA
[8] RONALD & NANCY REAGAN RES INST, BETHESDA, MD USA
[9] NIMH, BETHESDA, MD 20892 USA
[10] WASHINGTON UNIV, ST LOUIS, MO USA
[11] NIH, BETHESDA, MD 20892 USA
[12] UNIV SO CALIF, LOS ANGELES, CA USA
[13] UNIV PENN, PHILADELPHIA, PA 19104 USA
[14] UNIV WASHINGTON, SEATTLE, WA 98195 USA
[15] WESLEY WOODS GERIATR HOSP, ATLANTA, GA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1997年 / 278卷 / 16期
关键词
D O I
10.1001/jama.1997.03550160083043
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective.-A consensus conference on the diagnosis and treatment of Alzheimer disease (AD) and related disorders was organized by the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society on January 4 and 5, 1997, The target audience was primary care physicians, and the following questions were addressed: (1) How prevalent is AD and what are its risk factors? What is its impact on society? (2) What are the different forms of dementia and how can they be recognized? (3) What constitutes safe and effective treatment for AD? What are the indications and contraindications for specific treatments? (4) What management strategies are available to the primary care practitioner? (5) What are the available medical specialty and community resources? (6) What are the important policy issues and how can policymakers improve access to care for dementia patients? (7) What are the most promising questions for future research? Participants.-Consensus panel members and expert presenters were drawn from psychiatry, neurology, geriatrics, primary care, psychology, nursing, social work, occupational therapy, epidemiology, and public health and policy. Evidence.-The expert presenters summarized data from the world scientific literature on the questions posed to the panel. Consensus Process.-The panelists listened to the experts' presentations, reviewed their background papers, and then provided responses to the questions based on these materials, The panel chairs prepared the initial drafts of the consensus statement, and these drafts were read by all panelists and edited until consensus was reached. Conclusions.-Alzheimer disease is the most common disorder causing cognitive decline in old age and exacts a substantial cost on society, Although the diagnosis of AD is often missed or delayed, it is primarily one of inclusion, not exclusion, and usually can be made using standardized clinical criteria, Most cases can be diagnosed and managed in primary care settings, yet some patients with atypical presentations, severe impairment, or complex comorbidity benefit from specialist referral, Alzheimer disease is progressive and irreversible, but pharmacologic therapies for cognitive impairment and nonpharmacologic and pharmacologic treatments for the behavioral problems associated with dementia can enhance quality of life, Psychotherapeutic intervention with family members is often indicated, as nearly half of all caregivers become depressed, Health care delivery to these patients is fragmented and inadequate, and changes in disease management models are adding stresses to the system, New approaches are needed to ensure patients' access to essential resources, and future research should aim to improve diagnostic and therapeutic effectiveness.
引用
收藏
页码:1363 / 1371
页数:9
相关论文
共 86 条
[61]   Accuracy of clinical diagnosis of Alzheimer disease and clinical features of patients with non-Alzheimer disease neuropathology [J].
Rasmusson, DX ;
Brandt, J ;
Steele, C ;
Hedreen, JC ;
Troncoso, JC ;
Folstein, MF .
ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1996, 10 (04) :180-188
[62]   Apolipoprotein E genotyping in Alzheimer's disease [J].
Relkin, NR ;
Tanzi, R ;
Breitner, J ;
Farrer, L ;
Gandy, S ;
Haines, J ;
Hyman, B ;
Mullan, M ;
Poirer, J ;
Strittmatter, W ;
Folstein, M ;
Farlow, M ;
Mayeux, R ;
Petersen, R ;
Roses, A ;
Schenk, D ;
Small, G ;
VanGool, W ;
CookDeegan, R ;
Fleck, L ;
Kapp, M ;
Karlinsky, H ;
PericakVance, M ;
Post, S ;
Wolpert, C ;
Berg, L ;
Blass, J ;
Fletcher, J ;
Hegele, R ;
Khachaturian, Z ;
Selkoe, D ;
Thal, L ;
Whitehouse, P ;
Kwon, YG .
LANCET, 1996, 347 (9008) :1091-1095
[63]   IS SENILE DEMENTIA AGE-RELATED OR AGING-RELATED - EVIDENCE FROM METAANALYSIS OF DEMENTIA PREVALENCE IN THE OLDEST-OLD [J].
RITCHIE, K ;
KILDEA, D .
LANCET, 1995, 346 (8980) :931-934
[64]   The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial [J].
Rogers, SL ;
Friedhoff, LT ;
Apter, JT ;
Richter, RW ;
Hartford, JT ;
Walshe, TM ;
Baumel, B ;
Linden, RD ;
Kinney, FC ;
Doody, RS ;
Borison, RL ;
Ahem, GL .
DEMENTIA, 1996, 7 (06) :293-303
[65]   Frequency and characteristics of silent dementia among elderly Japanese-American men - The Honolulu-Asia aging study [J].
Ross, GW ;
Abbott, RD ;
Petrovitch, H ;
Masaki, KH ;
Murdaugh, C ;
Trockman, C ;
Curb, JD ;
White, LR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (10) :800-805
[66]   The role of cost-effectiveness analysis in health and medicine [J].
Russell, LB ;
Gold, MR ;
Siegel, JE ;
Daniels, N ;
Weinstein, MC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (14) :1172-1177
[67]   MISDIAGNOSIS IN DEMENTIA - COMPARISONS OF DIAGNOSTIC ERROR RATE AND RANGE OF HOSPITAL INVESTIGATION ACCORDING TO MEDICAL SPECIALITY [J].
RYAN, DH .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 1994, 9 (02) :141-147
[68]  
SAKAUYE KM, 1993, AM J GERIATR PSYCHIA, V1, P894
[69]  
SALZMAN C, 1995, AM J GERIAT PSYCHIAT, V3, P26, DOI 10.1097/00019442-199524310-00004
[70]   A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease [J].
Sano, M ;
Ernesto, C ;
Thomas, RG ;
Klauber, MR ;
Schafer, K ;
Grundman, M ;
Woodbury, P ;
Growdon, J ;
Cotman, DW ;
Pfeiffer, E ;
Schneider, LS ;
Thal, LJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (17) :1216-1222